Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 6727

First Posted Date: 2010-06-17

Last Posted Date: 2019-01-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7

Registration Number: NCT01145885

Locations: 🇭🇺
1230.23.36001 Boehringer Ingelheim Investigational Site, Budapest, Hungary

To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).

Phase 1

Terminated

Conditions: Healthy
Pain

Interventions: Drug: BI 660848
Drug: Placebo

First Posted Date: 2010-06-16

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT01145014

Locations: 🇩🇪
1284.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Drug Use Survey of RESPIMAT in Patients With COPD

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2010-06-16

Last Posted Date: 2014-03-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 361

Registration Number: NCT01145053

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

Completed

Conditions: Venous Thromboembolism

First Posted Date: 2010-06-08

Last Posted Date: 2014-01-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1676

Registration Number: NCT01139658

Locations: 🇫🇷
Boehringer Ingelheim Investigational Site 19, Lyon, France
🇫🇷
Boehringer Ingelheim Investigational Site 30, Angers, France
🇫🇷
Boehringer Ingelheim Investigational Site 40, Beauvais, France

and more 50 locations

A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin

Phase 2

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran etexilate
Drug: Warfarin

First Posted Date: 2010-06-03

Last Posted Date: 2014-03-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 174

Registration Number: NCT01136408

Locations: 🇯🇵
1160.49.014 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan
🇯🇵
1160.49.027 Boehringer Ingelheim Investigational Site, Iizuka,Fukuoka, Japan
🇯🇵
1160.49.013 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto, Japan

and more 25 locations

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: BIBF 1120

First Posted Date: 2010-06-03

Last Posted Date: 2015-01-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT01136174

Locations: 🇯🇵
1199.31.002 Boehringer Ingelheim Investigational Site, Bunkyo-ku,Tokyo, Japan
🇯🇵
1199.31.004 Boehringer Ingelheim Investigational Site, Hamamatsu, Shizuoka, Japan
🇯🇵
1199.31.006 Boehringer Ingelheim Investigational Site, Nagoya, Aichi, Japan

and more 5 locations

TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: telmisartan/amlodipine

First Posted Date: 2010-06-02

Last Posted Date: 2014-01-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 502

Registration Number: NCT01134393

Locations: 🇮🇹
1235.33.39009 Boehringer Ingelheim Investigational Site, Arezzo, Italy
🇮🇹
1235.33.39002 Boehringer Ingelheim Investigational Site, Bologna, Italy
🇩🇪
1235.33.49010 Boehringer Ingelheim Investigational Site, Berlin, Germany

and more 44 locations

Non-interventional Observational Study With Viramune® in HIV to Evaluate Gender Specific Data

Completed

Conditions: HIV Infections

First Posted Date: 2010-06-02

Last Posted Date: 2015-01-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 265

Registration Number: NCT01134939

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site 21, Leipzig, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 10, Berlin, Germany
🇩🇪
Boehringer Ingelheim Investigational Site 11, Berlin, Germany

and more 31 locations

to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Flibanserin plus Digoxin
Drug: Digoxin

First Posted Date: 2010-06-02

Last Posted Date: 2011-04-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01134965

Locations: 🇩🇪
511.158.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: BI 207127
Drug: Ribavirin
Drug: BI 201335
Drug: BI 207217

First Posted Date: 2010-05-28

Last Posted Date: 2016-02-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 488

Registration Number: NCT01132313

Locations: 🇺🇸
1241.21.0004 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
🇺🇸
1241.21.0012 Boehringer Ingelheim Investigational Site, Arlington, Texas, United States
🇺🇸
1241.21.0003 Boehringer Ingelheim Investigational Site, La Jolla, California, United States

and more 50 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy